Developer docs
API playgroundTry for free, no card

Search company profiles

LUMA Vision

Full company profile

uuid0000w2t

Namestring
LUMA Vision
Legal namestring
LUMA Vision Ltd.
Websiteurl
lumavision.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

LUMA Vision (formerly OneProjects), founded in 2017 by Fionn Lahart and Christoph Hennersperger, is an Irish-German privately held medical device company headquartered in Dublin with an engineering and R&D center in Munich. The company develops VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform designed for interventional electrophysiology (EP) and structural heart procedures. VERAFEYE integrates proprietary hardware — including a novel ultrasound-enabled catheter with an orbital, contact-free field of view — with a software processing engine and machine learning capabilities to deliver real-time, CT-quality volumetric visualization of the beating heart. Key features include Rapid Digital Anatomy (RDA), which reconstructs both atrial chambers in under 60 seconds, and magnetic tracking of third-party therapeutic catheters, enabling a streamlined two-catheter ablation workflow.

The company serves cardiac electrophysiologists and EP labs at hospitals and academic medical centers, targeting atrial fibrillation (AFib) ablation, complex arrhythmia treatment, and structural heart interventions. The intended customer pain point is the limited imaging visibility during endovascular procedures, where current 2D intracardiac echo and fluoroscopy produce repeat procedure rates of 2–4 times per patient. LUMA Vision's business model is anchored on capital equipment sales of the VERAFEYE platform combined with recurring single-use catheter consumables for ablation procedures, sold direct to leading cardiac hospitals and academic medical centers through an enterprise field-sales motion.

As of early 2026, LUMA Vision remains pre-commercial. The company has completed first-in-human procedures at Mater Private Network in Dublin (January 2025), run 15 procedures at KBC Split in Croatia in collaboration with CardioFocus, and enrolled patients in a Prague-based study. A 510(k) application has been submitted to the FDA with a commercial launch targeted for 2026. The company has raised approximately $51 million across multiple funding rounds from institutional investors including EQT Life Sciences, Atlantic Bridge Ventures, imec.xpand, the European Innovation Council, LSP, Bayern Kapital, and Enterprise Ireland, plus non-dilutive grant funding from the Disruptive Technologies Innovation Fund and the EIC Accelerator.

Short descriptiontext

LUMA Vision is an Irish-German medical device company developing VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform for interventional electrophysiology. It sells capital equipment and consumables to cardiac hospitals and EP labs targeting atrial fibrillation ablation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac imaging systems, electrophysiology navigation, 4D cardiac visualization, catheter ablation technology, intracardiac ultrasound imaging
Industry3 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Imaging Systems
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1VERAFEYE Platform System
TypeHardware Sales
Description

Sale of medical device capital equipment including the VERAFEYE imaging platform, catheter-based hardware, and associated software systems to hospitals and cardiac centers.

lumavision.com
2Catheter Consumables
TypeHardware Sales
Description

Single-use catheters and procedural consumables for cardiac ablation and electrophysiology procedures.

lumavision.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1VERAFEYE™
Description

A novel end-to-end platform technology providing 4D cardiac imaging and navigation for interventional electrophysiology and structural heart procedures. The platform delivers CT-quality visualization in seconds, combining live 2D and 4D intra-procedural imaging with digital anatomical models.

lumavision.com
Core offering1 text field

VERAFEYE is an end-to-end catheter-based 4D cardiac imaging and navigation platform that integrates a proprietary ultrasound-enabled orbital-view catheter, hardware console, software processing engine, and machine learning to provide real-time volumetric visualization of the beating heart during interventional electrophysiology procedures. The platform is sold as capital equipment to hospitals and cardiac centers, paired with single-use catheters as recurring consumables, and targets atrial fibrillation ablation and other complex arrhythmia interventions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CT-quality reconstructions of atrial chambers in under 60 seconds
+2 more records
Product overview1 text field

LUMA Vision operates at the intersection of hardware, software, and machine learning to deliver a single unified platform — VERAFEYE™ — for interventional cardiac imaging and navigation. VERAFEYE™ integrates a novel ultrasound-enabled catheter with orbital view imaging, a software-defined processing engine, and AI-powered features including the Rapid Digital Anatomy (RDA) module. The platform captures real-time 4D intracardiac imaging, magnetically tracks third-party catheters, and automatically reconstructs digital anatomical models, all within a single system designed to unify fragmented EP workflows. There are no standalone modules or separate product tiers — the VERAFEYE platform delivers its full capabilities as a cohesive end-to-end solution for cardiologists and electrophysiologists.

Product and service1 record
1VERAFEYE Visualization and Guidance Platform
CategoryCardiac Imaging Systems
Description

End-to-end, catheter-based 4D cardiac imaging and navigation platform providing real-time volumetric visualization of the beating heart, automatic digital anatomy generation, and magnetic tracking of third-party catheters for interventional electrophysiology and structural heart procedures. Sold as capital equipment to hospitals and cardiac centers performing catheter ablation for atrial fibrillation and other arrhythmias.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Collaboration for clinical study evaluating VERAFEYE-guided persistent atrial fibrillation ablation procedures. Demonstrated integration with CardioFocus ablation technology and streamlined two-catheter workflow.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Academic institution from which LUMA Vision was spun out, originating from BioInnovate Ireland program.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Medical device innovation program that provided the foundation and origin for LUMA Vision company.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

European Institute of Innovation and Technology Health initiative supporting healthcare innovation projects.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of robotic magnetic navigation systems for cardiac ablation procedures. Comparable as a smaller EP-focused technology company offering alternative catheter navigation in the same electrophysiology lab environment.

2Acutus Medical
TypeDirect peer
Description

Cardiac electrophysiology company developing mapping and imaging technologies for arrhythmia treatment. Closely comparable as a smaller EP-focused competitor with novel cardiac imaging/navigation technology targeting similar electrophysiologists.

TypeDirect peer
Description

Developer of catheter-based laser ablation systems for atrial fibrillation. Directly comparable as a strategic partner of LUMA Vision (collaborated on the KBC Split clinical study) targeting the same AF ablation procedure space.

TypeEmerging player
Description

Developer of advanced cardiac electrophysiology recording and 3D mapping systems. Comparable as a smaller EP-focused technology company providing mapping/imaging tools in the same electrophysiology lab setting.

TypeEmerging player
Description

Developer of catheter-based systems for atrial fibrillation treatment (Globe Mapping and Ablation System). Comparable emerging player targeting the same AF ablation indication with novel catheter-based technology.

TypeEmerging player
Description

Developer of catheter-based delivery systems for structural heart interventions including mitral and tricuspid valves. Comparable as a smaller catheter-based cardiac device company operating in the same interventional cardiology/structural heart space.

TypeEmerging player
Description

Developer of optically-based cardiac ablation and imaging catheter systems using photonics technology. Comparable emerging player in catheter-based cardiac ablation with novel imaging-enabled approach.

8Biosense Webster (Johnson & Johnson)
TypeBroad incumbent
Description

J&J's electrophysiology business and global leader in EP mapping and ablation catheters (CARTO system). Directly competes with VERAFEYE in the same cardiac EP labs and arrhythmia ablation procedures.

TypeBroad incumbent
Description

Major incumbent in cardiac EP with mapping systems (Rhythmia) and ablation catheters. Competes directly for the same EP lab capital equipment and procedural catheter purchases that VERAFEYE targets.

10Abbott
TypeBroad incumbent
Description

Broad medtech incumbent with significant EP portfolio including mapping systems (EnSite X) and ablation catheters. Competes with VERAFEYE for EP lab equipment, ablation workflows, and structural heart procedure guidance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LUMA Vision

Cardiac Imaging Systemslumavision.com

LUMA Vision is an Irish-German medical device company developing VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform for interventional electrophysiology. It sells capital equipment and consumables to cardiac hospitals and EP labs targeting atrial fibrillation ablation.

What LUMA Vision does

LUMA Vision (formerly OneProjects), founded in 2017 by Fionn Lahart and Christoph Hennersperger, is an Irish-German privately held medical device company headquartered in Dublin with an engineering and R&D center in Munich. The company develops VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform designed for interventional electrophysiology (EP) and structural heart procedures. VERAFEYE integrates proprietary hardware — including a novel ultrasound-enabled catheter with an orbital, contact-free field of view — with a software processing engine and machine learning capabilities to deliver real-time, CT-quality volumetric visualization of the beating heart. Key features include Rapid Digital Anatomy (RDA), which reconstructs both atrial chambers in under 60 seconds, and magnetic tracking of third-party therapeutic catheters, enabling a streamlined two-catheter ablation workflow.

The company serves cardiac electrophysiologists and EP labs at hospitals and academic medical centers, targeting atrial fibrillation (AFib) ablation, complex arrhythmia treatment, and structural heart interventions. The intended customer pain point is the limited imaging visibility during endovascular procedures, where current 2D intracardiac echo and fluoroscopy produce repeat procedure rates of 2–4 times per patient. LUMA Vision's business model is anchored on capital equipment sales of the VERAFEYE platform combined with recurring single-use catheter consumables for ablation procedures, sold direct to leading cardiac hospitals and academic medical centers through an enterprise field-sales motion.

As of early 2026, LUMA Vision remains pre-commercial. The company has completed first-in-human procedures at Mater Private Network in Dublin (January 2025), run 15 procedures at KBC Split in Croatia in collaboration with CardioFocus, and enrolled patients in a Prague-based study. A 510(k) application has been submitted to the FDA with a commercial launch targeted for 2026. The company has raised approximately $51 million across multiple funding rounds from institutional investors including EQT Life Sciences, Atlantic Bridge Ventures, imec.xpand, the European Innovation Council, LSP, Bayern Kapital, and Enterprise Ireland, plus non-dilutive grant funding from the Disruptive Technologies Innovation Fund and the EIC Accelerator.

LUMA Vision firmographics

Firmographics
Name
LUMA Vision
Legal name
LUMA Vision Ltd.
Website
https://lumavision.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
LUMA Vision is an Irish-German medical device company developing VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform for interventional electrophysiology. It sells capital equipment and consumables to cardiac hospitals and EP labs targeting atrial fibrillation ablation.
Ownership category
akta.pro rank

LUMA Vision industry classification

Industry
Product category
Cardiac Imaging Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)

Keywords

  • Cardiac imaging systems
  • Electrophysiology navigation
  • 4D cardiac visualization
  • Catheter ablation technology
  • Intracardiac ultrasound imaging

Where LUMA Vision is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices2 records

Markets served

LUMA Vision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. VERAFEYE Platform System: Sale of medical device capital equipment including the VERAFEYE imaging platform, catheter-based hardware, and associated software systems to hospitals and cardiac centers.
  2. Catheter Consumables: Single-use catheters and procedural consumables for cardiac ablation and electrophysiology procedures.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

LUMA Vision product offering

Product offering

Core offering

VERAFEYE is an end-to-end catheter-based 4D cardiac imaging and navigation platform that integrates a proprietary ultrasound-enabled orbital-view catheter, hardware console, software processing engine, and machine learning to provide real-time volumetric visualization of the beating heart during interventional electrophysiology procedures. The platform is sold as capital equipment to hospitals and cardiac centers, paired with single-use catheters as recurring consumables, and targets atrial fibrillation ablation and other complex arrhythmia interventions.

Product overview

LUMA Vision operates at the intersection of hardware, software, and machine learning to deliver a single unified platform — VERAFEYE™ — for interventional cardiac imaging and navigation. VERAFEYE™ integrates a novel ultrasound-enabled catheter with orbital view imaging, a software-defined processing engine, and AI-powered features including the Rapid Digital Anatomy (RDA) module. The platform captures real-time 4D intracardiac imaging, magnetically tracks third-party catheters, and automatically reconstructs digital anatomical models, all within a single system designed to unify fragmented EP workflows. There are no standalone modules or separate product tiers — the VERAFEYE platform delivers its full capabilities as a cohesive end-to-end solution for cardiologists and electrophysiologists.

Differentiator

Problem solved

Functional benefit

Brands

  • VERAFEYE™: A novel end-to-end platform technology providing 4D cardiac imaging and navigation for interventional electrophysiology and structural heart procedures. The platform delivers CT-quality visualization in seconds, combining live 2D and 4D intra-procedural imaging with digital anatomical models.

Products and services

  • VERAFEYE Visualization and Guidance Platform End-to-end, catheter-based 4D cardiac imaging and navigation platform providing real-time volumetric visualization of the beating heart, automatic digital anatomy generation, and magnetic tracking of third-party catheters for interventional electrophysiology and structural heart procedures. Sold as capital equipment to hospitals and cardiac centers performing catheter ablation for atrial fibrillation and other arrhythmias.

Quantifiable outcome

  • CT-quality reconstructions of atrial chambers in under 60 seconds
  • +2 more outcomes

Companies that use LUMA Vision

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

LUMA Vision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

LUMA Vision partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic, foundational and supporting.

  • CardioFocus, Inc.strategicStrategic or Co-development Partner · 7 January 2026Collaboration for clinical study evaluating VERAFEYE-guided persistent atrial fibrillation ablation procedures. Demonstrated integration with CardioFocus ablation technology and streamlined two-catheter workflow.
  • Trinity College DublinfoundationalStrategic or Co-development Partner · 1 January 2017Academic institution from which LUMA Vision was spun out, originating from BioInnovate Ireland program.
  • BioInnovate IrelandfoundationalStrategic or Co-development Partner · 1 January 2017Medical device innovation program that provided the foundation and origin for LUMA Vision company.
  • EIT HealthsupportingStrategic or Co-development Partner · 1 January 2017European Institute of Innovation and Technology Health initiative supporting healthcare innovation projects.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

LUMA Vision competitors and assessment

Company assessment

Direct peers

  • Stereotaxis: Developer of robotic magnetic navigation systems for cardiac ablation procedures. Comparable as a smaller EP-focused technology company offering alternative catheter navigation in the same electrophysiology lab environment.
  • Acutus Medical: Cardiac electrophysiology company developing mapping and imaging technologies for arrhythmia treatment. Closely comparable as a smaller EP-focused competitor with novel cardiac imaging/navigation technology targeting similar electrophysiologists.
  • CardioFocus: Developer of catheter-based laser ablation systems for atrial fibrillation. Directly comparable as a strategic partner of LUMA Vision (collaborated on the KBC Split clinical study) targeting the same AF ablation procedure space.

Emerging players

  • CathVision: Developer of advanced cardiac electrophysiology recording and 3D mapping systems. Comparable as a smaller EP-focused technology company providing mapping/imaging tools in the same electrophysiology lab setting.
  • Kardium: Developer of catheter-based systems for atrial fibrillation treatment (Globe Mapping and Ablation System). Comparable emerging player targeting the same AF ablation indication with novel catheter-based technology.
  • NaviGate Cardiac Structures: Developer of catheter-based delivery systems for structural heart interventions including mitral and tricuspid valves. Comparable as a smaller catheter-based cardiac device company operating in the same interventional cardiology/structural heart space.
  • MedLumics: Developer of optically-based cardiac ablation and imaging catheter systems using photonics technology. Comparable emerging player in catheter-based cardiac ablation with novel imaging-enabled approach.

Broad incumbents

  • Biosense Webster (Johnson & Johnson): J&J's electrophysiology business and global leader in EP mapping and ablation catheters (CARTO system). Directly competes with VERAFEYE in the same cardiac EP labs and arrhythmia ablation procedures.
  • Boston Scientific: Major incumbent in cardiac EP with mapping systems (Rhythmia) and ablation catheters. Competes directly for the same EP lab capital equipment and procedural catheter purchases that VERAFEYE targets.
  • Abbott: Broad medtech incumbent with significant EP portfolio including mapping systems (EnSite X) and ablation catheters. Competes with VERAFEYE for EP lab equipment, ablation workflows, and structural heart procedure guidance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LUMA Vision social profiles

Digital presence

LUMA Vision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LUMA Vision leadership team

Management profile

Number of profiles

Profiles13 records

LUMA Vision funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LUMA Vision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LUMA Vision

What does LUMA Vision do?

VERAFEYE is an end-to-end catheter-based 4D cardiac imaging and navigation platform that integrates a proprietary ultrasound-enabled orbital-view catheter, hardware console, software processing engine, and machine learning to provide real-time volumetric visualization of the beating heart during interventional electrophysiology procedures. The platform is sold as capital equipment to hospitals and cardiac centers, paired with single-use catheters as recurring consumables, and targets atrial fibrillation ablation and other complex arrhythmia interventions.

Is LUMA Vision a public or private company?

LUMA Vision is a private company. It is classified as venture growth investor backed and is currently operating.

When was LUMA Vision founded?

LUMA Vision was founded in 2017. It employs 51 to 100 people.

Where is LUMA Vision based?

LUMA Vision is headquartered in Dublin, Ireland, in the Europe region.

How does LUMA Vision make money?

Two revenue lines are on record. VERAFEYE Platform System is the primary driver. The others are catheter Consumables.

Who are LUMA Vision's main competitors?

Direct peers on record are Stereotaxis, Acutus Medical and CardioFocus. Emerging players are CathVision, Kardium, NaviGate Cardiac Structures and MedLumics. Broad incumbents are Biosense Webster (Johnson & Johnson), Boston Scientific and Abbott.

Does LUMA Vision have an API?

No public API is recorded for LUMA Vision.

What industry is LUMA Vision in?

LUMA Vision's product category is Cardiac Imaging Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLUMA Vision Secures FDA Clearance Advancing Procedural Intelligence as the Foundation of the Cardiac Lab of the FutureLUMA Vision announced FDA clearance for its VERAFEYE procedural intelligence platform, which unifies imaging, visualization, navigation, and guidance for cardiac procedures. The system reconstructs 3D heart anatomy with CT-like accuracy and tracks catheters in real time. Commercial launch is planned for early 2027, with future expansion into LAA and structural heart.PR NewswireLUMA Vision to Showcase VERAFEYE 4D Imaging Platform at HRS 2026, Signaling a New Foundation for EP GuidanceLUMA Vision announced its participation in the Heart Rhythm Society Annual Meeting (HRS 2026) in Chicago, where it will showcase its VERAFEYE™ Visualization and Guidance Platform for real-time 4D cardiac imaging and navigation. The platform delivers CT-quality visualization in seconds, combining live 2D and 4D intra-procedural imaging with digital anatomical models to support faster, more precise electrophysiology procedures. CEO Fionn Lahart positioned VERAFEYE as a foundational AI-powered operating layer designed to unify fragmented EP workflows and become the standard for cardiac procedure guidance.PR NewswireLUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.LUMA Vision announced the expansion of its VERAFEYE™ 4D navigation and imaging platform clinical program, with first patient enrollments in two European studies at Na Homolce Hospital in Prague and KBC University Hospital in Split, evaluating the system for guiding catheter ablation procedures using multiple Pulsed Field Ablation technologies. The company has submitted a 510(k) application for the latest VERAFEYE™ iteration, initiating the regulatory approval process ahead of a planned commercial launch in 2026. The milestones were highlighted during a joint visit by Ireland's and Bavaria's Ministers of Health to LUMA Vision's Munich facility, emphasizing European collaboration in cardiac healthcare innovation.PR NewswireLUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.LUMA Vision announced the expansion of its VERAFEYE™ 4D cardiac imaging platform clinical program, with first patient enrollments in two European studies at Na Homolce Hospital in Prague and KBC University Hospital in Split, evaluating the system for guiding catheter ablation procedures. The company simultaneously submitted a 510(k) application to the FDA for regulatory approval, with plans for commercial launch in 2026 targeting enhanced indications for cardiac electrophysiology procedures. The milestones were highlighted during a joint visit by Ireland's and Bavaria's Ministers for Health to LUMA Vision's Munich facility, emphasizing European DeepTech and MedTech collaboration.MorningstarLUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.LUMA Vision has expanded its VERAFEYE™ clinical program with first patient enrollments in two European studies evaluating the 4D imaging and navigation platform for guiding atrial fibrillation catheter ablation procedures at hospitals in Prague and Split. The company has submitted a 510(k) application to the FDA for regulatory clearance of the latest VERAFEYE™ iteration, with commercial launch planned for 2026. The expansion was highlighted during a joint visit by Ireland's and Bavaria's Ministers for Health to LUMA Vision's Munich facility, underscoring European collaboration in cardiac healthcare innovation.PR NewswireLUMA Vision VERAFEYE System to be Featured at AF Symposium In Recorded Case PresentationLUMA Vision Ltd. announced that its VERAFEYE™ System, a next-generation cardiac 4D navigation and imaging platform, will be featured in a recorded clinical case presentation at the AF Symposium on February 6. The case, presented by Dr. Ante Anić of University Hospital Split, is part of a clinical study that has completed 15 cases, with Dr. Anić reporting the system has meaningfully streamlined procedures by generating high-quality digital anatomy and real-time 2D visualization. The company stated it is preparing for a U.S. market launch later this year, though the system's navigation features are not yet approved for commercial use.PR NewswirePrecision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac CareLUMA Vision Ltd. announced the successful completion of 15 VERAFEYE™-guided persistent atrial fibrillation ablation procedures as part of a clinical study conducted in collaboration with CardioFocus, Inc. at KBC Split, Croatia. The study demonstrated VERAFEYE's ability to integrate high-resolution intracardiac imaging with navigation and automatically generated digital anatomy, enabling a streamlined two-catheter ablation workflow with real-time 4D visualization of the beating heart. The company aims to bring this technology to a broader global market in 2026.PR NewswirePrecision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac CareLUMA Vision announced the successful completion of 15 VERAFEYE™-guided persistent atrial fibrillation ablation procedures as part of a clinical study conducted in collaboration with CardioFocus. The study demonstrated VERAFEYE's ability to integrate high-resolution intracardiac imaging and navigation with automatically generated digital anatomy, enabling a streamlined two-catheter ablation workflow with real-time four-dimensional visualization of the beating heart. CEO Fionn Lahart stated the company aims to bring this technology to a broader global market in 2026.The Irish TimesIrish cardiac imaging medtech Luma Vision wins US regulatory clearanceLuma Vision, an Irish cardiac imaging company, received US FDA clearance for its Verafeye Visualisation Platform, a catheter-mounted sensor system for 360-degree heart imaging. The device targets arrhythmias like atrial fibrillation and marks the company's first market approval. It plans to submit a next product to the FDA later this year.PR NewswireLUMA Vision Successfully Completes First-in-Human Procedures with its Novel VERAFEYE™ Navigation and Visualization PlatformLUMA Vision announced the successful first-in-human procedures using its VERAFEYE™ platform, a catheter-based imaging system designed to improve visualization in cardiac electrophysiology. The procedures at the Mater Private Network in Dublin demonstrated the system's potential to enhance procedural accuracy, speed, and safety.